Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
  Phillip Investor Notes

15-06-2018(Fri) 14-06-2018(Thu) 13-06-2018(Wed) 12-06-2018(Tue) 11-06-2018(Mon)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes *Advertisement*
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
15 Jun, 2018 (Friday)

Jacobson Pharma Corporation (2633) is principally engaged in the production and sale of generic drugs and proprietary medicines. The Group strives to expand its product portfolio, production capacity and markets. With regard to generic drugs, the Group actively introduces new products under its R&D pipeline in order to tap into the high growth segments. The Group`s new manufacturing plant at Synco (H.K.) Limited, equipped with advanced and high throughput PIC/S GMP compliant facilities, has commenced operation since September last year. Additionally, the Group continues to enhance brand management, marketing and sales of its proprietary medicines business and expansion of its sales platform in Hong Kong, mainland China and Asia Pacific regions. (I do not hold the above stock)
Buy-in Price: $2.05, Target Price: $2.25, Cut Loss Price: $1.95

YH operates over 600 supermarket in 21 China provinces and cities, operating GAF reaching 5mn sqm. It promotes cooperation with JD and 401 supermarkets have already combined with JD logistic system, which means consumers` orders in YH online shop can be delivered and finished by JD logistic within one hour. Meanwhile, YH promotes renovation upgrade projects. With smart management system to be launched, 30% electricity fees can be saved. In 2017, the company revenue reached RMB58.6bn (+19% YoY), NP attributable to shareholders totaled RMB1.82bn (+46.3% YoY) and NP excluding non-recurring items amounted to RMB1.78bn (+63.6% YoY). In 18Q1, company revenue rose up by 23% to RMB18.77bn, but NP excluding items only grew by 2.42% YoY to RMB745mn due to increasing expenses, (+RMB0.76bn selling expenses, +RMB0.35bn management fees due to stock option scheme).
Buy-in Price: $8.25, Target Price: $9.50, Cut Loss Price: $7.80

Shanghai Pharma (2607.HK) - Proposed Further Acquisition of Techpool

Investment Summary

SPH announced further acquisition of Techpool with a consideration of USD144mn (RMB915mn). We highlight that long-run benefits from further acquisition and potential increase in both sales volume and ASP after BE test. We estimate EPS to be RMB1.48/1.69 in 18E/19E. Assuming target PE 14.25x (roughly par to 2-y historical PE), we maintain target price of HKD25.5. (Exchange rate= 0.823 RMB/HKD) (Closing price at 12 Jun 2018)

Business Overview

Proposed further acquisition of Techpool. SPH plans to acquire Techpool with a consideration of USD144mn (RMB915mn), implying target PE 18.6x based on Techpool 3-y average earnings. After closing the transaction, the company will increase the share from 40.8% to 67.14%, absolute control of Techpool. Techpool, a global leader inhuman urine protein bio-pharmaceuticals enterprises, set up in 1994, is engaged in R&D, production and distribution of biopharmaceuticals, focusing on critical medicine field. Techpool's two core products: (1) national second-class new drug Tianpuluoan (domestic exclusive species), applicable to acute and chronic pancreatitis and acute circulatory failure (shock), and widely used in ICUs. Tianpuluoan's coverage rate in tertiary and secondary hospitals has reached 60% in cities, covering 80% of total number of ICU beds and realizing a sales revenue of RMB1,064mn/1,098mn/81mn in FY15-17; and (2) Kailikang, the new drug of global origination, for the treatment of mild to moderate acute thrombotic cerebral infarction, reported sales revenue of RMB31mn/342mn/276mn during FY15-17.

Transaction to enrich product mix and intensify network. We appreciate Techpool's competitiveness in natural bio-protein field. Key products, like Tianpuan and Kailikang, are believed to have substantial market potential and will further diversify SPH product mix, which helps to strengthen SPH's manufacturing segment. SPH will continue to increase investment in R&D and introduction of variety license-in. With its vertical-intensive national distribution network and a mature marketing team focused on critical disease field, Techpool is expected to increase marketing promotion capability of SPH and further improve SPH's marketing system. Leveraging on SPH's platform, Techpool is expected to further improve its market penetration and share, as well as steep up the development of innovative business (like IVD equipment agents in the PRC).

Consistency test to drive hike both in volume and price. China government published policies to facilitate the replacement of original imported drug with generic drug. It indicates that qualified generic drugs should be included into public purchase lists and be paid just as original drugs. We are positive that drugs` sales volume and ASP will rise after passing consistency test. SPH now has 70 products under consistency evaluation, and the number of evaluated products is leading in across China. During 18Q1, SPH finished the evaluation of newly-added metformin hydrochloride sustained-release tablets and submits to CFDA, and finished the application of 3 varieties and has put nearly 1/2 products into the stage of clinical research. Earlier players passing the test are likely to take more market share in advance.

Financial review. Its 18Q1 revenue reached RMB36.39bn (+9.83% YoY), NP attributable to shareholders amounted to RMB1.02bn (+2.07%) and NP excluding non-recurring items totaled in RMB996mn (+6.08%). By segment, manufacturing continued high growth and retail business accelerated, while distribution business to benefit from industry integration in long term.

Valuation and Risks

Our model gives target price of HKD25.5. With assumed 2018 PE of 14.25x (roughly par to 2-y historical average) and estimated 18E/19E EPS of RMB1.48/1.69, we get target price HKD25.5. Risks include: 1) Proposed acquisition fail expectation; 2) Two-invoice system affects inventory allotment business; 3) Consistency evaluation progresses not well; 4) Policy risk. (Exchange rate= 0.823 RMB/HKD)


Click Here for PDF format...

Recommendation on 15-6-2018
Price on Recommendation Date$ 22.850
Suggested purchase priceN/A
Target Price$ 25.500
Writer Info
Eurus Zhou
(Research Analyst)
Tel: +852 2277 6515

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%

A-H spread
Stock Code H share
A share
H share

Oversea Research Reports

Investment Service Centre

Enquiry : 2277 6666 OR
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2018 Phillip Securities (HK) Ltd. All Rights Reserved.

Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]